Nele, developmental biologist and geneticist in heart and soul, is a science editor with The Scientist’s Creative Services Team. She writes to inspire scientists and improve the academic research culture.
Cystic fibrosis (CF) is a devastating hereditary disease that causes persistent lung infections, which limit a patient’s ability to breathe over time. While recent therapeutic breakthroughs improve patient life expectancy, many ultimately succumb to CF because available therapies fail to protect against respiratory infections. Researchers have struggled to develop better treatments because few preclinical models replicate key CF features and enable rigorous drug testing, but hope is on the horizon.1
In a recent study published in the Journal of Cystic Fibrosis, Don Ingber and his group at the Wyss Institute of Biologically Inspired Engineering presented the CF airway chip—a new in vitro model engineered with patient cells.2 This chip, which mimics the pathological hallmarks of the disease, will allow scientists to better understand CF pathogenesis and screen for more effective drugs to treat the disorder in patients with diverse genetic backgrounds and comorbidities.
Ingber has spent a large part of ...
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Nele earned her PhD in developmental biology from Baylor College of Medicine. During her graduate and postgraduate training, she developed gene editing technologies for characterizing human disease genes in flies and mice. Nele loves combining science communication and advocacy. She runs a blog for early career scientists and promotes open, reproducible science. In July 2021, Nele joined The Scientist’s Creative Services Team as an assistant science editor.
In this half-day virtual summit, a series of presentations will explore the scientific, regulatory, and operational factors impacting the use of in vitro NAMs in drug discovery.
Chief Business Officer Dr. Rob Burgess Shares How Sino Biological Is Empowering Global Biomedical Research Through Precision, Quality, and Innovation on an Exclusive Segment on Fox Business Network airing on February 1, 2026 at 4:30pm EST
Sino Biological, Inc. has announced the accelerated availability and development of critical research tools to support the global scientific community in combating NiV.
The ranking places Refeyn among a cohort of high-growth UK technology firms spanning sectors including the life sciences, energy and sustainability, telecommunications, and digital technology.
